Gladius Capital Management’s Thermo Fisher Scientific TMO Stock Holding History

Gladius Capital Management’s Portfolio TMO Stock Details TMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,800	Closed	-$955K	–	415
2023 Q4	$955K	Sell	1,800 -2,700	-60%	-$1.31M	0.15%	87
2023 Q3	$2.28M	Buy	4,500 +400	+10%	+$213K	0.1%	109
2023 Q2	$2.14M	Buy	4,100 +1,000	+32%	+$540K	0.1%	84
2023 Q1	$1.79M	Buy	+3,100	New	+$1.75M	0.1%	89
2021 Q4	–	Sell	-1,200	Closed	-$686K	–	315
2021 Q3	$686K	Hold	1,200	–	–	0.05%	65
2021 Q2	$606K	Sell	1,200 -7,400	-86%	-$3.49M	0.06%	77
2021 Q1	$3.92M	Sell	8,600 -1,900	-18%	-$907K	0.15%	105
2020 Q4	$4.89M	Buy	10,500 +7,400	+239%	+$3.47M	0.24%	96
2020 Q3	$1.37M	Buy	+3,100	New	+$1.28M	0.14%	76
2020 Q1	–	Sell	-1,300	Closed	-$423K	–	177
2019 Q4	$423K	Hold	1,300	–	–	0.03%	143
2019 Q3	$379K	Hold	1,300	–	–	0.02%	185
2019 Q2	$390K	Buy	+1,300	New	+$358K	0.02%	143

Other funds holding TMO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Gladius Capital Management's TMO Position: Q3 2024 in Review

Gladius Capital Management sold out of Thermo Fisher Scientific (TMO) in Q3 2024, closing a stake of 3,710 shares — an estimated $2.05M sold.

Gladius Capital Management first reported a position in TMO in Q3 2019 and held it in 14 quarters. The position peaked at $2.85M in Q3 2023. 2,568 funds tracked by Wall St. Rank hold TMO as of Q3 2024.

Gladius Capital Management reported no remaining Thermo Fisher Scientific position as of Q3 2024 after selling out during the quarter.
Gladius Capital Management sold 3,710 Thermo Fisher Scientific shares in Q3 2024, an estimated $2.05M.
Gladius Capital Management first reported a position in Thermo Fisher Scientific in Q3 2019 and held it in 14 quarters.
Gladius Capital Management's Thermo Fisher Scientific position peaked at $2.85M in Q3 2023.
2,568 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q3 2024.

Based on Gladius Capital Management's 13F filing for Q3 2024, filed 6 Nov 2024.